Aortic Aneurysm, Thoracic
44
1
8
21
Key Insights
Highlights
Success Rate
84% trial completion
Published Results
11 trials with published results (25%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
9.1%
4 terminated out of 44 trials
84.0%
-2.5% vs benchmark
9%
4 trials in Phase 3/4
52%
11 of 21 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 21 completed trials
Clinical Trials (44)
Evaluation of the GORE® Ascending Stent Graft
Evaluation of the GORE® TBE Device in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta, Zone 2
Detection of Hypoxia in Human Thoracic Aorta Using Pimonidazole Hydrochloride
Endovascular Treatment of TAAA and Aortic Arch Aneurysms Using Fenestrated and Branched Stent Grafts
Antibiotic Prophylaxis for TEVAR
Investigation of the Neurovegetative Pattern in Patients With Thoracic Aortic Aneurysms (TAA)
Thoraflex Hybrid Post-Market Study
Aortic Dilatation Under 5 cm: Genetic Risk Mapping
Evaluation of the GORE® TBE Device in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta, Zone 0/1
RelayPro Thoracic Stent-Graft in Subjects With Thoracic Aortic Aneurysms and Penetrating Atherosclerotic Ulcers
Proximal Aortopathy in Scotland - Epidemiology and Surgical Outcomes
GORE® TAG® Thoracic Endoprosthesis French Mandatory Registry
Valiant Evo US Clinical Trial
Valiant Evo International Clinical Trial
REgistRy BRAnch goRE EndopRosthEsis
VALIANT CAPTIVIA Post-market Registry
Risk of Rupture of Aneurysms of the Thoracic Ascending Aorta (ATA) From the Dynamic Imaging
LANDMARC Study: a Study With Focus on Aorta Ascendens
TOtal tRansfemoral branCHed endovasCular tHoracoabdominal Aortic Repair Registry
Feasibility Study for GORE® TAG® Thoracic Branch Endoprosthesis to Treat Proximal Descending Thoracic Aortic Aneurysms